Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

This study is comparing two approaches after first-line chemotherapy (anthracycline-based treatment) for advanced soft tissue sarcoma: continuing with a second chemotherapy drug (pegylated liposomal doxorubicin, or PLD) versus active surveillance (watchful waiting without immediate further treatment). It is for patients whose cancer did not worsen during initial chemotherapy. **You may be eligible if...** - You are 18 or older with a confirmed advanced soft tissue sarcoma - Your cancer responded to or remained stable during 4 to 8 cycles of first-line anthracycline-based chemotherapy - Your cancer can still be measured on scans (per standard criteria) - You can be enrolled within 8 weeks of your last chemotherapy dose - You are in reasonably good health **You may NOT be eligible if...** - Your sarcoma is a subtype that typically does not respond to chemotherapy (e.g., alveolar soft part sarcoma, clear cell sarcoma, solitary fibrous tumor) - You have significant heart disease (prior anthracyclines can affect heart function) - You have progressive or worsening disease after first-line treatment Talk to your doctor to see if this trial is right for you.